Zanamivir

A neuraminidase inhibitor (antiviral agent), which has been recently approved for the treatment of acute uncomplicated influenza infection, because it reduces replication of influenza A and B viruses. It is most effective for influenza, if started within a few hours of onset of symptoms.

Brands

RELENZA ROTADISK

Adult Dose

Neonatal

Paedriatic

Characteristics

Contraindications

Zanamivir is contraindicated in conditions like Breast feeding.

Effects

The symptomatic adverse reactions produced by Zanamivir are more or less tolerable and if they become severe, they can be treated symptomatically, these include Rashes, Bronchospasm, GI disturbance, Respiratory impairment.

Indications

Zanamivir is primarily indicated in conditions like Acid-related dyspepsia, Influenza.

Interactions

No data regarding the interactions of Zanamivir was found.

Interfrence

Risks

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Warnings

Zanamivir should be used with caution in patients with asthma and chronic pulmonary disease (risk of bronchospasm----short-acting bronchodilator should be available; avoid in severe asthma unless close monitoring possible and appropriate facilities available to treat bronchospasm); uncontrolled chronic illness; other inhaled drugs should be administered before Zanamivir; pregnancy (use only if potential benefit outweighs risk).

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.